Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why GSK plc (LSE:GSK) Is on Investors’ Radar: FTSE 100 Outlook for November 2026

For aBusinessactive in vaccines and specialty pharmaceuticals, sentiment can move faster than the underlying economics.Market Participantsmay respond to company announcements, sector valuations and expectations for monetary policy, but an identifiable same-day share-price catalyst should not be assumed in the absence of a confirmed announcement. …

Ankur Sharma | 02 November 2026

Haleon (LSE:HLN) in Focus: FTSE 100 Investors Weigh the Next Turning Point

The FTSE 100 context matters because benchmark flows can influenceDemandfor listed shares, particularly when investors rotate between domestic cyclicals, defensives and businesses with international revenues. However, anindexlabel should not be confused with a company catalyst. Price movements can reflect broad positioning, currency expectations and …

Ankur Sharma | 02 November 2026

Why Kooth PLC (LSE:KOO) Is on Investors’ Radar: FTSE AIM All-Share Outlook for November 2026

For aBusinessactive in digital mental health support services, sentiment can move faster than the underlying economics.Market Participantsmay respond to company announcements, sector valuations and expectations for monetary policy, but an identifiable same-day share-price catalyst should not be assumed in the absence of a confirmed …

Ankur Sharma | 02 November 2026

Oxford Biomedica (LSE:OXB) in Focus: FTSE 250 Investors Weigh the Next Turning Point

The FTSE 250 context matters because benchmark flows can influenceDemandfor listed shares, particularly when investors rotate between domestic cyclicals, defensives and businesses with international revenues. However, anindexlabel should not be confused with a company catalyst. Price movements can reflect broad positioning, currency expectations and …

Ankur Sharma | 02 November 2026

Why AstraZeneca PLC (LSE:AZN) Is on Investors’ Radar: FTSE 100 Outlook for November 2026

For aBusinessactive in global pharmaceuticals and drug development, sentiment can move faster than the underlying economics.Market Participantsmay respond to company announcements, sector valuations and expectations for monetary policy, but an identifiable same-day share-price catalyst should not be assumed in the absence of a confirmed …

Ankur Sharma | 02 November 2026

Why CRISM Therapeutics Corporation (LSE:CRTX) Is on Investors’ Radar: FTSE AIM All-Share Outlook for November 2026

For aBusinessactive in drug delivery and pharmaceutical development, sentiment can move faster than the underlying economics.Market Participantsmay respond to company announcements, sector valuations and expectations for monetary policy, but an identifiable same-day share-price catalyst should not be assumed in the absence of a confirmed …

Ankur Sharma | 02 November 2026

CVS Group (LSE:CVSG) in Focus: FTSE 250 Investors Weigh the Next Turning Point

The FTSE 250 context matters because benchmark flows can influenceDemandfor listed shares, particularly when investors rotate between domestic cyclicals, defensives and businesses with international revenues. However, anindexlabel should not be confused with a company catalyst. Price movements can reflect broad positioning, currency expectations and …

Ankur Sharma | 02 November 2026

Why EKF Diagnostics Holdings plc (LSE:EKF) Is on Investors’ Radar: FTSE AIM All-Share Outlook for November 2026

For aBusinessactive in diagnostic testing instruments and healthcare products, sentiment can move faster than the underlying economics.Market Participantsmay respond to company announcements, sector valuations and expectations for monetary policy, but an identifiable same-day share-price catalyst should not be assumed in the absence of a …

Ankur Sharma | 02 November 2026

Spire Healthcare (LSE:SPI) shareholders approve £1.03bn takeover scheme with 99.9% of votes

Spire Healthcare (LSE:SPI) Group plc announced on 30 October 2026 that its shareholders had approved the proposed acquisition by Tulip UK Bidco Limited (Bidco) at meetings held that day. Bidco is a newly formed company indirectly owned by a consortium of funds managed or …

Ankur Sharma | 02 November 2026

AstraZeneca (LSE:AZN) lifts Q3 Core EPS 19% at CER and reconfirms 2026 guidance

Chief Executive Pascal Soriot said the group is "on track to deliver our 2030 ambition and to sustain growth through the next decade". (LSE:AZN) He added that "Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars." …

Ankur Sharma | 02 November 2026
Support

Hi! How can we help you today?

Loading…